Other novel promising biomarkers are emerging, such as the detection of circulating tumor DNA (ctDNA), gains in CD274 gene (which encodes for PD-L1), expression of major histocompatibility complex (MHC)-II on tumor cells, and gene-expression profiles (GEPs). This evidence concerns the gene CD274 and neoplasm.